26 | Tumor size may predict early response to sonidegib in locally-advanced basal cell carcinoma: clinical and histopathological correlates from a monocentric case series
Gabriella Perillo1, Giovanni Cecchi1, Biancamaria Zuccaro1, Federica Fazzari1, Vincenzo De Giorgi1|2 | 1Section of Dermatology, Department of Health Sciences, University of Florence; 2Cancer Research "Attilia Pofferi" Foundation, Pistoia, Italy.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: Sonic Hedgehog (SHH) inhibitors, including sonidegib, have emerged as effective therapies for locally advanced basal cell carcinoma (LA-BCC). However, variability in clinical response has been observed.
Objective: to evaluate the correlation between clinical and histopathological characteristics and the initial response to sonidegib in a monocentric series of LA-BCC cases.
Methods: A retrospective analysis of 15 patients with LA-BCC treated with sonidegib was conducted. Tumor subtypes and clinical features were correlated with time to initial response using ERIVANCE BCC composite criteria.
Results: The mean time to initial clinical response was 15.4 weeks. Tumors >3 cm showed significantly faster response (13.4 weeks) compared to tumors <3 cm (24 weeks), a finding not previously reported. Pigmentation and patient age also showed moderate impact on response time, while histological subtype and other features had less influence.
Conclusions: Tumor size appears to be an important predictor of early response to sonidegib (Figure 1). Larger lesions may exhibit greater metabolic activity, enhancing drug response. These findings merit further validation in larger cohorts.
Figure 1.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
